相关实验视频

Updated: Jan 8, 2026

Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections

Quantitative Immunohistochemistry of the Cellular Microenvironment in Patient Glioblastoma Resections

Published on: July 31, 2017

超突变的模式塑造了不匹配修复缺陷质瘤中的瘤发生和免疫治疗反应

Nicholas R Fernandez¹, Yuan Chang¹, Nuno M Nunes¹

¹Arthur and Sonia Labatt Brain Tumour Research Centre, Toronto, Ontario, Canada.

Nature genetics

|December 22, 2025

概括

不匹配修复缺陷高度质瘤 (MMRD-HGG) 根据DNA聚合酶或IDH1突变显示出不同的子组. 这些子组影响治疗反应,DNA聚合酶突变MMRD-HGG对免疫治疗有反应.

科学领域:

神经瘤学神经瘤学
基因组学就是基因组学.
癌症生物学癌症生物学

背景情况:

主要不匹配修复缺陷的高度质瘤 (priMMRD-HGG) 是一种侵略性的脑瘤.
这些瘤表现出高突变和对标准治疗的耐药性,对免疫治疗的反应不可预测.

研究的目的:

研究推动 priMMRD-HGG 发展的基因组机制.
了解这些机制如何影响患者的治疗结果和治疗敏感性.

主要方法:

分析了来自162名 priMMRD-HGG 患者的基因组和临床数据.
根据二次驱动突变 (复制性DNA聚合酶或IDH1) 来识别子组.
评估基因组不稳定性,突变特征和甲基化模式.

主要成果:

鉴定出了三个不同的priMMRD-HGG子组,其特征是不同的基因组不稳定机制和突变特征 (点突变与副本数量改变).
特别地,MMRD特征驱动TP53和IDH1中的突变,与常见的儿科质瘤驱动因素有所不同.
DNA聚合酶突变priMMRD-HGG显示出超高突变和免疫热微环境,与免疫治疗反应相关.
IDH1-突变的prMMRD-HGG的特征是免疫冷和抵抗免疫疗法.

结论:

由MMRD驱动的质生成涉及非随机的突变发生模式,定义了不同的瘤亚型.
基于二次驱动因素 (DNA聚合酶与IDH1突变) 的子组分类预测了免疫治疗反应.
研究结果为开发针对性和基于免疫的治疗策略提供了一个框架,用于 priMMRD-HGG.

更多相关视频

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures

Published on: January 9, 2019

Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation

Primary Orthotopic Glioma Xenografts Recapitulate Infiltrative Growth and Isocitrate Dehydrogenase I Mutation

Published on: January 14, 2014

相关概念视频

Mismatch Repair

Mismatch Repair

Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...

Mismatch Repair

Mismatch Repair

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.